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Background: Postural tachycardia syndrome (POTS) is a heterogeneous disorder that creates challenges for treatment.
Beta-blocker was one of the most commonly used drugs, but it is inconsistently effective. The purpose of this study is to
explore whether orthostatic plasma norepinephrine level could be an indicator of therapeutic effectiveness of
metoprolol for POTS in children.
Methods: Twenty-seven children with POTS were enrolled in our study. They received metoprolol treatment, and their
orthostatic plasma norepinephrine levels were measured by high-performance liquid chromatography method. Three
months after rmetoprolol treatment, 25 patients were followed up. A receiver-operating characteristic (ROC) curve was
used to explore the predictive value of orthostatic plasma norepinephrine level.
Results: The symptom severity and increment of heat rate from supine position to upright of patients positively
correlated with their orthostatic plasma norepinephrine level (r = 0.599, P < 0.001; r = 0.633, P <0.001, respectively).
Orthostatic plasma norepinephrine level in responders to metoprolol was significantly higher than that of
nonresponders (P = 0.028). A ROC curve on the predictive value of orthostatic plasma norepinephrine level
showed that the area under the curve was 0.785. Using a cutoff value for orthostatic plasma norepinephrine level
of 3.59 pg/ml yielded both sensitivity (76.9%) and specificity (91.7%) in predicting the efficacy of metoprolol
therapy for POTS.
Conclusion: Orthostatic plasma norepinephrine level of > 3.59 pg/ml was an indicator of the effectiveness of
metoprolol therapy for POTS in children and adolescents.
Keywords: Norepinephrine, Postural tachycardia syndrome, MetoprololBackground
Postural tachycardia syndrome (POTS) is a heteroge-
neous disorder characterized by sustained tachycardia
(≥30 bpm in adults and ≥40 bpm in children) upon
standing, and relief of these symptoms with recumbence.
Although the underlying causes of POTS remain un-
clear, several mechanisms have been proposed, including
sympathetic activation, hypovolemia, and partial auto-
nomic neuropathy [1-4]. POTS is associated with a poor
quality of life and significantly functional disability [5].* Correspondence: junbaodu1@126.com
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unless otherwise stated.There is a paucity of effective therapies [1,4]. Because of
the striking tachycardia that is central to this disorder,
these patients are often referred to cardiologists for diag-
nosis and treatment. Given that excessive tachycardia is
a cardinal feature of this syndrome, a logical treatment
strategy would be reducing the HR with β-adrenergic
blockade. β-blockers have been reported to improve
symptoms in case reports and open-label studies [6-10].
Unfortunately, it is inconsistently effective [11,12]. Differ-
ences in noradrenergic activity between hyperadrenergic
and other types of POTS may explain this inconsistency,
and previous studies of efficacy of β-blockers in POTS
subjects did not stratify participants into POTS sub-
types according to their underlying causes. Hyperadrener-
gic subgroup with β-blockers would seem reasonable.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in healthy subjects [13]. Higher-dose of β-blocker might
worsen symptoms of patients with POTS, which raises the
concern that the effectiveness of β-blockers in POTS
might depend on noradrenergic activity of patients with
POTS. Our hypothesis is that the orthostatic plasma nor-
epinephrine level could help guiding β-blocker therapy in
the management of POTS in children.
Methods
Subjects
Twenty-seven children (mean age, 11 years, ranging from
6 years to 15 years) were diagnosed as POTS at the De-
partment of Pediatrics, Peking University First Hospital.
Our study referred to the following criteria [14-17]: 1) a
child has a normal heart rate at supine and no evidence of
any cardiovascular diseases; 2) after standing up or getting
up, a child has 2 of the following symptoms: dizziness,
chest distress, chest pain, headache, palpitation, pale face,
amaurosis, fatigue, discomfort, or syncope; 3) these symp-
toms should be relieved or diminished by recumbence,
and the symptoms should occur repeatedly for 1 month;
4) in addition to the symptoms of orthostatic intolerance,
POTS is diagnosed with the quantitative sign of a heart rate
increase of 40 beats/min or greater or a heart rate of > 120
beats/min within the first 10 min after standing during
head-up test (HUT) or head-up tilt test (HUTT); simultan-
eously, the decrease of blood pressure should be < 20/
10 mm Hg; and 5) children with other diseases that cause
symptoms of autonomic nervous system (such as anemia,
arrhythmia, hypertension, or endocrine disorders including
pheochromocytoma or hyperthyroidism) as well as cardio-
genic or neurogenic diseases that would induce syncope
were excluded. The study has been conducted according to
the principles expressed in the Declaration of Helsinki.
The written informed consent had been obtained from
each individual and their parents and the study protocol
was approved by the Ethics Committee of Peking University
First Hospital (the approval number: 2012 [525]).
HUTT protocol
All patients received tilt table testing. All examinations
occurred between 8:00 AM and 10:00 AM in a quiet and
bland light room at a comfortable constant ambient
temperature (22°C, 50% to 55% humidity). Patients were
secured to a tilt table, and HR and BP were monitored
for 10 min. Patients were then tilted upward at angle of
60° for 45 min. Then, blood pressure and heart rate were
monitored and electrocardiogram was recorded simul-
taneously during the test (Dash 2000 Monitor, GE Com-
pany, U.S.A). The patients were placed in the supine
from the standing position as soon as the positive re-
sponse or symptoms of orthostatic intolerance (OI) oc-
curred. The symptoms of OI included lightheadedness,diminished concentration, tremulousness, nausea, head-
ache, near syncope or syncope. A sustained heart rate in-
crease ≥ 40 beats/min or a sustained rate of 120 beats/
min in the first 10 min of passive upright tilt is consid-
ered diagnostic [17,18].
Assay orthostatic plasma norepinephrine
After patients rested for 30 min or longer, they remained
standing position for 5 min, and then blood samples were
collected. Blood samples were centrifuged at 3,000 rpm
for 10 min immediately after collection, and plasma was
frozen for −20°C until analysis. Plasma catecholamine
levels were determined by high-performance liquid chro-
matography with electrochemical detection [19].
Protocol of treatment and follow-up
All 27 patients were prescribed metoprolol for therapy.
The dose of metoprolol was 0.5 mg/kg daily, twice a day.
Follow-up in our cardiology clinic was conducted after
3 month of therapy, and the children and their parents
were asked to report any changes in symptoms of ortho-
static intolerance.
POTS symptoms were evaluated in children with the se-
verity of symptoms for symptom scores [17,20,21]. Symp-
tom score criteria: the following symptoms: dizziness,
headache, shortness of breath, gastrointestinal symptoms,
fatigue, pallor, blurred vision, palpitations, sweating, tremu-
lousness, according to their frequency of OI symptoms
graded from 0 to 4. Score 0 stands for no symptoms occur-
rence during follow up; score 1: 1 episode of OI symptom
occurrence per month; score 2: 2 to 4 episodes of symp-
toms occurrence per month; score 3: 2 to 7 episodes of
symptoms occurrence per week; 4: more often once daily.
The therapy was determined to be effective, when the
symptom of OI disappeared or symptoms scores decreased
less than 50 percent [22].
Statistical analysis
Statistical analysis was done using SPSS13.0 (SPSS Inc,
Chicago, IL, USA). Continuous variables were compared
using Student’s t-test and analysis of variance; categorical
variables were compared using Fisher’s exact test, and
qualitative variables were compared using Pearson’s
chi-square test. A P value <0.05 was considered to be statis-
tically significant. The relationship between symptom sever-
ity and increment of heat rate from supine position to
standing with orthostatic plasma norepinephrine level in
children with POTS was analyzed using the Pearson correl-
ation test. A receiver-operating characteristic (ROC) curve
was utilized to evaluate the predictive value of orthostatic
plasma norepinephrine level in assessing the therapeutic ef-
fect of metoprolol. The area under the curve represents the
predictive value, with an area of 0.5-0.7 indicating low pre-
dictive value, 0.7-0.9 indicating a moderate predictive value,
Figure 1 Scatter plot and trend line of symptoms score and
orthostatic plasma norepinephrine level of patients with POTS.
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the area under the curve did not contain 0.5, or if the P
value was <0.05, it was suggested that orthostatic plasma
norepinephrine level was a reliable predictor of the thera-
peutic effect of metoprolol in treating children with POTS.
Results
Mean age for all 27 POTS patients was 11 ± 6 years, ran-
ging from 6 to 15 years. There was female predominance
(females: males: 15:12). The mean BMI of 27 patients was
18.6 ± 3.7. Supine HR and BP were shown in Table 1.
Patients with severe symptoms had a high level of
orthostatic plasma norepinephrine. Pearson correlation
analysis revealed a significant positive correlation be-
tween symptom severity and orthostatic plasma norepin-
ephrine (r =0.599; P < 0.001) (Figure 1). Increment of
heat rate from supine position to standing of patients
with POTS also had a significantly positive correlation
with orthostatic plasma norepinephrine through Pearson
correlation analysis (r =0.633; P < 0.001) (Figure 2).
During follow-up period, 2 patients did not reply des-
pite multiple attempts at making contact. Thus, we ana-
lyzed clinical symptoms and hemodynamic changes
before and after metoprolol treatment in 25 patients.
Both their symptom scores and their tachycardia during
HUT or HUTT were decreased obviously, when com-
pared with those before treatment (Table 2).
In the 25 patients with POTS, who received metoprolol
for therapy, 13 patients were responders, with their symp-
tom disappearance or symptoms scores decrease less than
50 percent. The pre-treatment data, such as age, sex,
symptom scores, supine blood pressure and changes in
heart rates during HUT, did not differ between the 13
metoprolol responders and 12 nonresponders (Table 1).
The results showed that metoprolol responders had
higher plasma levels of norepinephrine than the nonre-
sponders, and the difference was obvious (P < 0.05; Table 1).
The ROC curve (Figure 3) of plasma norepinephrine, for
predicting the therapeutic effect of metoprolol, showedTable 1 Comparison of baseline characteristics in responders
Characteristics Respo
Cases (n = 25)* 13
Age, years 12 ± 2
BMI, kg/m2* 19.7 ±
Females/males, n 7/6
Symptoms score before treatment 7.4 ± 1
Supine systolic BP, mmHg 101.9
Supine diastolic BP, mmHg 58.0 ±
Supine hear rate, beats/min 74.0 ±
Orthostatic plasma norepinephrine level, pmol/ml 5.10 ±
*Two out of 27 cases lost during follow-up.that the area under the ROC curve was 0.785 (95% confi-
dence interval: 0.591 to 0.980, P < 0.05). Using a cutoff
value for plasma levels of norepinephrine of 3.59 pg/ml
(to convert to pg/mL, multiply by the molecular weight of
norepinephrine) yielded a sensitivity of 76.9% and specifi-
city of 91.7% in predicting the effect of metoprolol for
treating POTS (Figure 3).
Discussion
Our findings showed a clear association between the
orthostatic plasma norepinephrine level and symptom
severity in patients with POTS. The orthostatic plasma
norepinephrine level of POTS patients also associated
with the increment of heat rate from supine position to
standing. Especially, we found that the effectiveness of
metoprolol in POTS children was related to the level of
orthostatic plasma norepinephrine. Our results indicate
that plasma level of norepinephrine > 3.59 pg/ml is an
indicator of the effectiveness of metoprolol in children
and adolescents with POTS.
Children with POTS often have symptoms of OI, such
as syncope, dizziness, chest distress, chest pain, headache,and nonresponders
nders Nonresponders P value
12
11 ± 3 0.655
4.9 17.2 ± 2.5 0.130
6/6 0.716
.9 7.2 ± 2.7 0.820
± 9.3 98.0 ± 8.6 0.286
9.7 55.1 ± 8.1 0.426
9.4 75.6 ± 9.8 0.683
2.69 2.93 ± 1.79 0.028
Figure 2 Scatter plot and trend line of increment of heat rate
from supine position to upright and orthostatic plasma
norepinephrine level of patients with POTS.
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Figure 3 ROC curve of predictive value of orthostatic plasma
norepinephrine level for distinguishing responders and
non-responders to metoprolol treatment. The y-axis represents
the sensitivity to predict the therapeutic response to metoprolol
treatment in patients with POTS; the x-axis, the false positive rate
(1 = specificity). Area under the curve was 0.785 (95% confidence
interval: 0.591 to 0.980, P < 0.05).
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current symptoms usually create physical and psycho-
logical stresses in children’s daily lives, both at home and
school [5,23,24]. Therefore, an effective treatment, to im-
prove symptoms, is necessary for the children with POTS.
No definite cause of primary POTS has been identified
[1-4]. Exaggerated postural tachycardia may reflect several
pathophysiologically distinct mechanisms. Although the
precise mechanism for POTS has not been determined,
given that excessive tachycardia is a cardinal feature of this
syndrome, a logical treatment strategy would be to reduce
the HR with β-adrenergic blockade. Raj et al. reported that
low-dose oral propranolol significantly attenuated tachy-
cardia and improved symptoms in POTS, and higher-dose
propranolol did not further improve, and might worsen
symptoms [8]. Arnold et al. also found recently that pro-
pranolol could improve HR control and exercise capacity
in POTS when given at the low doses of propranolol for
treatment [10]. We also found that metoprolol plus oral
saline was effective in the treatment of POTS in children
[9]. But in experimental models of orthostatic intolerance,
neither propranolol, nor esmolol was found to improveTable 2 Comparisons of symptom scores, changes of heart ra
Treatment
Responders (n = 13)
Symptoms scores Delta HR (beats
Pre-treatment 7.4 ± 1.9 55.2 ± 12.7
Post-treatment 0.4 ± 1.1 27.4 ± 7.8
P value <0.001 <0.001orthostatic tolerance [25-27], and Fu et al’ study suggested
that for patients with POTS, propranolol was not superior
to exercise training at restoring upright hemodynamics,
normalizing renal-adrenal responsiveness, and improving
quality of life [11]. The reasons for the different efficacy of
β-blockers for treatment of POTS were differences of nor-
adrenergic activity among distinct pathophysiological sub-
types of POTS. Thieben et al. described 3 groups of
patients: “hypovolemic”, “hyperadrenergic”, and “auto-
immune” groups [28]. Clearly, not all cases of POTS are
caused by hyperadrenergic state. Hyperadrenergic subgroup
with β-blockers would seem reasonable. Thus, identifying
an indicator to predict the effectiveness of β-blockers in
these patients is important.
Increases in orthostatic plasma norepinephrin are the
core of the biochemical changes of hyperadrenergic
POTS patients. Thus, we hypothesized that orthostatic
plasma norepinephrine level could predict the effectivenesste in POTS children treated by metoprolol
Nonresponders (n = 12)
/min) Symptoms scores Delta HR (beats/min)
7.2 ± 2.7 43.6 ± 8.7
5.0 ± 2.2 32.3 ± 9.7
<0.001 0.001
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the present study, we found that higher orthostatic plasma
norepinephrine level was associated with severer symp-
toms in children and adolescents with POTS, and there
was also a positive correlation between heart rate incre-
ment on HUTT and orthostatic norepinephrine levels.
These findings suggested that the excessive increase in
orthostatic norepinephrine levels may result from impaired
baroreflex-mediated vasoconstriction on standing in pa-
tients with POTS. These results are in keeping with previ-
ous studies of a prospective cohort of adult patients with
POTS [29].
To examine the possible predictive value of plasma
orthostatic norepinephrine levels, we used ROC analysis
and showed that plasma levels of orthostatic norepin-
ephrine had sensitivity of 76.9% and specificity of 91.7%
in predicting the efficacy of metoprolol for treating
POTS. Therefore, the plasma level of orthostatic nor-
epinephrine could be taken as one of the reference indi-
ces in choosing medication for children with POTS.
The present study has limitations. The small sample
size might have led to bias. Furthermore, we did not de-
tect the orthostatic plasma norepinephrine level of
healthy children as control group and the orthostatic
plasma norepinephrine levels after the treatment of
metoprolol, which was the limitation of the study. Fur-
ther studies are needed to increase the case number in
the multi-center design and analyze the plasma norepin-
ephrine levels in a more comprehensive aspect. It is
known that hyperadrenergic state has been well recog-
nized one of the important mechanisms for POTS, and
present study firstly provided the information about the
role of plasma norepinephrine as a biomarker to predict
the effect of treatment of metoprolol on POTS children.
Conclusion
Our findings suggest that the orthostatic plasma nor-
epinephrine level could be of great help in selecting
metoprolol therapy in the management of POTS in chil-
dren and adolescents. The findings are of great import-
ance for the individual therapeutic strategy of POTS in
children and adolescents.
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